生物制剂治疗银屑病及在相关皮肤病中的研究进展  

Research Progress of Biologics in the Treat-ment of Psoriasis and Related Skin Diseases

作　　者：魏子芝 郭砚[2] 

机构地区：[1]青海大学研究生院,青海?西宁 [2]青海大学附属医院皮肤性病科,青海?西宁

出　　处：《临床医学进展》2023年第6期10240-10247,共8页Advances in Clinical Medicine

摘　　要：银屑病作为炎症性和系统性疾病,它具有起病慢和易复发的特点,遗传、免疫和环境三种因素共同作用介导了银屑病的发生。局限或广泛分布的鳞屑样红斑或斑块为其典型的临床表现。银屑病的治疗包括外用药物、系统药物、物理治疗以及生物制剂,这些治疗主要改善其症状来提高患者的生活质量。目前很多临床试验表明,对于常规系统治疗无效或耐受性差的中至重度银屑病和(或)银屑病性关节炎患者可使用生物制剂,为患者能够带来持久疗效、长期安全和使用便捷等。生物制剂主要是针对炎症细胞因子,如TNF-α、IL-12/23和IL-17A等发挥作用的,也就是主要的免疫因素,阻断其发展,疗效显著。主要的生物制剂有乌司奴单抗、司库奇尤单抗、利妥昔单抗等,目前一些新的数据表明,生物制剂对共同炎症细胞因子的疾病也是有效果的,如寻常型天疱疮、玫瑰糠疹、扁平苔癣、毛发红糠疹和系统性硬化症患者是有效的。As an inflammatory and systemic disease, psoriasis, which induced by genetic, immune and envi-ronmental factors, it is characterized by slow onset and easy recurrence. The typical clinical mani-festations are squamous erythema or plaques, localized or widespread. Psoriasis treatment in-cludes topical medications, systemic medications, physical therapy, and biologics that improve symptoms and improve quality of life. Currently, many clinical trials have shown that biologics can be used clinically, particularly for patients with moderate to severe psoriasis and/or psoriatic ar-thritis who do not respond to conventional systemic therapy or are poorly tolerated. Biologics can bring lasting efficacy, long-term safety and ease of use for patients. Biological agents mainly target inflammatory cytokines, such as TNF-α, IL-12/23 and IL-17A, which are the main immune factors, and block their development, with significant effect. The main biologics include ulsinumab, scucci-umab, rituximab, etc. At present, some new data show that biologics are also effective for diseases with common inflammatory cytokines, such as pemphigus vulgaris, pityriasis rosea, lichenus planus, pityriasis rufuris pilaris and systemic sclerosis patients.

关 键 词：生物制剂 炎症细胞因子 白细胞介素12、23、17、22 皮肤病 综述 

分 类 号：R75[医药卫生—皮肤病学与性病学]